Market Research Logo

Global Precision Medicine Market

Global Precision Medicine Market

The advancement and innovation of new healthcare technologies are developing the platform for the growth of precision medicine market. Since, the announcement of ‘Precision Medicine Initiative’ by the President Barack Obama in January, 2015, a large number of research and development has been taken for the development of precise drugs, targeted therapeutics, and laboratory tests. Presently, the main focus of the government initiatives is toward oncology, but it is anticipated to target almost all therapeutic areas affected by genetic mutations.

Governmental regulations and standards are sustaining the growth and development of the precision medicine market. The main aim of these regulations is to make precision medicines more adaptable and focused towards genetic diseases related to Oncology, skin, respiratory, CNS, CVD, and infectious diseases among others. The patients are benefitted indirectly by these regulations as it save time and cut-down cost as the patients get the required treatment for the specific disease.

The growth in the precision medicine market is propelled by an increasing demand for personalized treatment, technological innovation and advancement (including Biomarker-based tests/kits, next gene sequencing, and precise imaging), Government support and regulations, and these have created a demand for the precision medicine solutions.

Our study includes an overview and analysis of the precision medicine market by ecosystem, sub-markets, therapeutics and geographical regions, allowing the research to develop a comprehensive outlook of the market. The precision medicine market report presents detailed analysis of the entire precision medicine ecosystem and provides extensive insights of the different developments, trends and key participants. The report also focuses on different sub-markets which help in the development of precision medicine solutions. The sub-market verticals are categorized into five major categories, viz. companion diagnostics, biomarkers, targeted therapeutics, Pharmacogenomics and molecular diagnostics among others in the report.

Further, the scope of the report includes the therapeutics of different disease types managed by this technology. All of the above mentioned report coverage parameters are discussed across different regions like The Americas, Europe, Asia Pacific (APAC) and Rest of the World (ROW).

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliance, and regulatory bodies and their involvement in the precision medicine market.

The answers to the following key questions can be found in the report:

  • What are the major market drivers, challenges and opportunities of the precision medicine market and their use cases?
  • What are the primary precision medicine market trends and key developments for different precision medicine systems?
  • What are the key developmental strategies in different applications across all regions in this market?
  • What are different types of precision medicine solutions and the latest precision medicine technologies?
  • How will the key market players leverage on key developments such as Mergers and Acquisitions, Partnerships, and Product Launches among others?
  • Which geographical region will lead the global precision medicine market by the end of the forecast period?
  • Who are the key players in the precision medicine market?
  • What kind of government regulations have been implemented for different precision medicine solutions?
  • What are the different types of sub-markets in precision medicine market and what are the applications in which they are being used?
  • What is the different used case scenarios considered under different applications?
  • What are the different therapeutic applications in which precision medicine products are being used?
  • What are the precision medicine market trends and key developments in different geographical regions?
This research tries to answer various aspects of the precision medicine market such as major factors driving the market, threats that can possibly slow down the market growth, and the current growth opportunities that are going to shape the market expansion of precision medicine solutions. The research study incorporates Porter’s Five Force Model for in-depth analysis of the precision medicine market and an assessment of the factors governing it. The report builds itself upon a comprehensive value chain giving a clear understanding of ecosystem of precision medicine market penetration.

Towards the end of the report, the readers will have a clear understanding of the market dynamics, major drivers and the underlying threats and challenges that the global precision medicine industry is subjected to, including the estimation of the industry’s growth in terms of production and revenue.

The report includes the profiles of major players in the precision medicine market that allows its readers to get an insight into the industry trends. Some of the leading companies in the precision medicine market are Abbott Laboratories, Almac Group Ltd. and Caris Life sciences among others.


1 REPORT SCOPE
1.1 SCOPE OF THE STUDY
1.2 PRECISION MEDICINE: REPORT COVERAGE
1.3 BIS RESEARCH METHODOLOGY
1.3.1 RESEARCH METHODOLOGY FOR THE GLOBAL MARKET STUDY
1.3.1.1 GEOGRAPHICAL ANALYSIS
1.3.1.2 DEMAND SIDE & SUPPLY SIDE ANALYSIS
1.3.1.3 DATA SYNTHESIS AND BRIDGING
1.3.2 GLOBAL PRECISION MEDICINE: RESEARCH METHODOLOGY
1.3.2.1 KEY DATA POINT SOURCES
1.3.2.1.1 DATA POINTS TAKEN FROM SECONDARY SOURCES
1.3.2.1.2 DATA POINTS TAKEN FROM PRIMARY SOURCES
1.4 REPORT DESCRIPTION
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET TIMELINE
3.3 KEY PARTICIPANTS, STRATEGIES & DEVELOPMENTS
3.3.1 GOVERNMENT AGENCIES
3.3.2 ACADEMIC INSTITUTIONS
3.3.3 DEVICE & SERVICE PROVIDERS
3.4 KEY MARKET STRATEGIES AND DEVELOPMENTS
3.4.1 INTRODUCTION
3.4.2 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
3.4.3 MERGERS & ACQUISITIONS
3.4.4 PRODUCT DEVELOPMENT AND LAUNCH
3.4.5 BUSINESS EXPANSION/CONTRACTS
3.4.6 PATENTS, APPROVALS AND CERTIFICATIONS
3.4.7 OTHERS (EVENTS & RECOGNITIONS)
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 MARKET DRIVERS
4.2.1 PATIENTS INVOLVEMENT IN PERSONAL HEALTHCARE
4.2.2 TECHNOLOGIES DRIVING THE MARKET (E.G. NEXT-GENERATION SEQUENCING TECHNOLOGIES, ULTRA-HIGH THROUGHPUT SEQUENCING)
4.2.3 INCREASE IN GENETIC DISEASES
4.2.4 POTENTIAL FOR MORE TARGETED THERAPIES
4.2.5 INTEGRATION OF BIG DATA HEALTHCARE COMPANIES WITH PHARMA & BIOTECH COMPANIES
4.3 MARKET CHALLENGES
4.3.1 POTENTIAL THREAT TO PERSONAL DATA
4.3.2 HIGH DIAGNOSTIC COST AS A BARRIER
4.3.3 POTENTIAL RISK OF HARDWARE OR SOFTWARE FAILURE
4.3.4 STRINGENT REGULATIONS AND STANDARDS
4.3.5 LACK OF AWARENESS ABOUT THE POSSIBLE APPLICATIONS OF PRECISION MEDICINE
4.3.6 REIMBURSEMENT POLICIES AND REGULATORY FRAMEWORK
4.3.7 LIMITED KNOWLEDGE ABOUT THE APPLICATION OF TEST AND TECHNIQUES
4.3.8 LACK OF RESEARCH AND EVIDENCES CREATING HINDRANCES IN ITS APPLICATION
4.4 MARKET OPPORTUNITIES
4.4.1 INTRODUCTION OF PRECISION MEDICINE SOLUTIONS IN DEVELOPING ECONOMIES
4.4.2 DOWNSIZING THE COST OF GENOME SEQUENCING TO THREE DIGITS
5 INDUSTRY DYNAMICS
5.1 VALUE CHAIN ANALYSIS
5.1.1 DEVICE MANUFACTURER & DRUG PRODUCERS
5.1.2 HEALTHCARE PROVIDERS
5.1.3 HEALTHCARE ITS OR BIG DATA COMPANIES
5.1.4 REGULATORS
5.1.5 THIRD PARTY PAYERS
5.1.6 PATIENTS
5.2 PORTER FIVE FORCE ANALYSIS
5.2.1 BARGAINING POWER OF BUYER (PATIENT)
5.2.2 BARGAINING POWER OF SUPPLIER
5.2.3 THREAT FROM SUBSTITUTE
5.2.4 THREAT FROM A NEW ENTRANT
5.2.5 INTENSITY OF COMPETITIVE RIVALRY
5.3 CONSORTIUMS, CERTIFICATION, REGULATIONS, AND STANDARDS
5.3.1 INTRODUCTION
5.3.2 REGULATORY BODIES
5.3.2.1 FOOD AND DRUG ADMINISTRATION (FDA)
5.3.2.2 MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA)
5.3.2.3 THERAPEUTIC GOODS ADMINISTRATION (TGA)-AUSTRALIA
5.3.2.4 CONFORMITÉ EUROPÉENNE (CE)
5.3.3 CONSORTIUMS
5.3.4 ALLIANCES/ASSOCIATIONS
6 GLOBAL PRECISION MEDICINE MARKET BY ECOSYSTEM PLAYERS
6.1 INTRODUCTION
6.1.1 MARKET STATISTICS
6.2 PHARMACEUTICALS AND BIOTECHNOLOGY COMPANIES
6.2.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
6.2.1.1 MARKET TRENDS
6.2.1.2 MARKET DEVELOPMENTS
6.2.1.3 KEY PARTICIPANTS
6.3 DIAGNOSTIC COMPANIES
6.3.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
6.3.1.1 MARKET TRENDS
6.3.1.2 MARKET DEVELOPMENTS
6.3.1.3 KEY PARTICIPANTS
6.4 HEALTHCARE IT SPECIALISTS/ BIG DATA COMPANIES
6.4.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
6.4.1.1 MARKET TRENDS
6.4.1.2 MARKET DEVELOPMENTS
6.4.1.3 KEY PARTICIPANTS
6.5 CLINICAL LABORATORIES
6.5.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
6.5.1.1 REGULATORY BODIES AND COMPLIANCES
6.5.1.2 MARKET TRENDS
6.5.1.3 KEY PARTICIPANTS
7 GLOBAL PRECISION MEDICINE MARKET BY SUB-MARKETS
7.1 INTRODUCTION
7.1.1 MARKET STATISTICS
7.2 COMPANION DIAGNOSTICS
7.3 BIOMARKER-BASED TEST
7.3.1 ROLE OF BIOBANKING INTO BIOMARKER
7.3.2 KEY PARTICIPANTS
7.4 TARGETED THERAPEUTICS
7.4.1 KEY PARTICIPANTS
7.5 PHARMACOGENOMICS (PGX)
7.5.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
7.5.1.1 MARKET TRENDS
7.5.1.2 MARKET DEVELOPMENTS
7.5.1.3 KEY PARTICIPANTS
7.6 MOLECULAR DIAGNOSTICS
7.7 OTHERS
7.7.1 NEXT-GENERATION SEQUENCING
7.7.2 CONSUMER GENOMICS
7.7.2.1 KEY PARTICIPANTS
7.7.3 3D PRINTING
8 GLOBAL PRECISION MEDICINE MARKET BY THERAPEUTICS
8.1 INTRODUCTION
8.1.1 MARKET STATISTICS
8.2 CANCER/ONCOLOGY
8.2.1 MARKET STATISTICS
8.2.2 TYPES OF CANCER
8.2.3 DRUGS & TESTS
8.2.4 KEY MARKET TRENDS, DEVELOPMENTS & PARTICIPANTS
8.2.4.1 MARKET TRENDS
8.2.4.2 MARKET DEVELOPMENTS
8.2.4.3 KEY PARTICIPANTS
8.3 CARDIOVASCULAR DISEASE (CVD)
8.3.1 MARKET STATISTICS
8.3.2 DRUGS & TESTS
8.3.3 MARKET TRENDS & MARKET DEVELOPMENTS
8.3.3.1 MARKET TREND
8.3.3.1.1 MARKET DEVELOPMENTS
8.3.3.1.2 KEY PARTICIPANTS
8.4 CENTRAL NERVOUS SYSTEM
8.4.1 MARKET STATISTICS
8.4.2 NEUROLOGICAL
8.4.2.1 NEUROLOGICAL DRUGS & TESTS
8.4.3 PSYCHIATRIC DISORDERS
8.4.3.1 PSYCHIATRIC DISORDER DRUGS & TESTS
8.4.4 MARKET TENDS & MARKET DEVELOPMENTS
8.4.4.1 MARKET TRENDS
8.4.4.2 KEY DEVELOPMENTS
8.4.4.3 KEY PARTICIPANTS
8.5 INFECTIOUS DISEASES
8.5.1 MARKET STATISTICS
8.5.2 INFECTIOUS DISEASES DRUGS & TESTS
8.5.3 MARKET DEVELOPMENTS & PARTICIPANTS
8.5.3.1 KEY DEVELOPMENTS
8.5.3.2 KEY PARTICIPANTS
8.6 OTHERS
8.6.1 MARKET STATISTICS
8.6.2 MARKET TRENDS, DEVELOPMENTS & PARTICIPANTS
8.6.2.1 MARKET TRENDS
8.6.2.2 KEY DEVELOPMENTS
8.6.2.3 KEY PARTICIPANTS
9 GLOBAL PRECISION MEDICINE MARKET BY GEOGRAPHY
9.1 INTRODUCTION
9.1.1 MARKET STATISTICS
9.2 THE AMERICAS
9.2.1 NORTH AMERICA
9.2.1.1 THE U.S.
9.2.1.2 CANADA
9.2.1.3 OTHERS
9.2.1.4 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
9.2.1.4.1 REGULATIONS AND COMPLIANCES
9.2.1.4.2 MARKET TRENDS
9.2.1.4.3 MARKET DEVELOPMENTS
9.2.1.4.4 KEY PARTICIPANTS
9.2.2 SOUTH AMERICA
9.2.2.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
9.2.2.1.1 REGULATIONS AND COMPLIANCES
9.2.2.1.2 MARKET TRENDS
9.2.2.1.3 KEY PARTICIPANTS
9.3 EUROPE
9.3.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
9.3.1.1 REGULATIONS AND COMPLIANCES
9.3.1.2 MARKET DEVELOPMENTS
9.3.1.3 KEY PARTICIPANTS
9.4 ASIA-PACIFIC (APAC)
9.4.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
9.4.1.1 MARKET DEVELOPMENTS
9.4.1.2 KEY PARTICIPANTS
9.5 REST OF THE WORLD/MIDDE EAST & AFRICA (MEA)
9.5.1 AFRICA
9.5.2 MIDDLE EAST
9.5.3 KEY MARKET DEVELOPMENTS AND PARTICIPANTS
9.5.3.1 MARKET DEVELOPMENTS
9.5.3.2 KEY PARTICIPANTS
10 COMPANY PROFILES
10.1 ABBOTT LABORATORIES
10.1.1 OVERVIEW
10.1.2 FINANCIALS
10.1.2.1 OVERALL FINANCIALS
10.1.2.2 FINANCIALS BY SEGMENT
10.1.2.3 FINANCIALS BY REGION
10.1.3 KEY DEVELOPMENTS
10.1.4 SWOT ANALYSIS
10.2 ALMAC GROUP, LTD.
10.2.1 OVERVIEW
10.2.2 FINANCIALS
10.2.3 KEY DEVELOPMENTS
10.2.4 SWOT ANALYSIS
10.3 ASURAGEN, INC.
10.3.1 OVERVIEW
10.3.2 FINANCIALS
10.3.3 KEY DEVELOPMENTS
10.3.4 SWOT ANALYSIS
10.4 BIOMÉRIEUX SA
10.4.1 OVERVIEW
10.4.2 FINANCIALS
10.4.2.1 OVERALL FINANCIALS
10.4.2.2 FINANCIALS BY REGION
10.4.2.3 FINANCIALS BY SEGMENT
10.4.3 KEY DEVELOPMENTS
10.4.4 SWOT ANALYSIS
10.5 CEPHEID INC.
10.5.1 OVERVIEW
10.5.2 FINANCIALS
10.5.2.1 OVERALL FINANCIALS
10.5.2.2 NET REVENUE BY SEGMENT
10.5.2.3 NET REVENUE BY REGION
10.5.3 KEY DEVELOPMENTS
10.5.4 SWOT ANALYSIS
10.6 CETICS HEALTHCARE TECHNOLOGIES GMBH
10.6.1 OVERVIEW
10.6.2 FINANCIALS
10.6.3 KEY DEVELOPMENTS
10.6.4 SWOT ANALYSIS
10.7 GE HEALTHCARE
10.7.1 OVERVIEW
10.7.2 FINANCIALS
10.7.2.1 OVERALL FINANCIALS
10.7.2.2 NET REVENUE BY SEGMENT
10.7.2.3 FINANCIAL SUMMARY
10.7.3 KEY DEVELOPMENTS
10.8 GLAXOSMITHKLINE PLC (GSK)
10.8.1 OVERVIEW
10.8.2 FINANCIALS
10.8.2.1 OVERALL FINANCIALS
10.8.2.2 FINANCIALS BY SEGMENT
10.8.2.3 FINANCIALS BY REGION
10.8.2.4 FINANCIALS BY THERAPEUTICS
10.9 INTOMICS A/S
10.9.1 OVERVIEW
10.9.2 FINANCIALS
10.9.3 KEY DEVELOPMENTS
10.9.4 SWOT ANALYSIS
10.10 JOHNSON & JOHNSON
10.10.1 OVERVIEW
10.10.2 FINANCIALS
10.10.2.1 OVERALL FINANCIALS
10.10.2.2 NET REVENUE BY SEGMENT
10.10.2.3 NET REVENUE BY REGION
10.10.3 KEY DEVELOPMENTS
10.11 LABORATORY CORPORATION OF AMERICA HOLDINGS
10.11.1 OVERVIEW
10.11.2 FINANCIALS
10.11.2.1 OVERALL FINANCIALS
10.11.2.2 FINANCIALS BY SEGMENT
10.11.3 KEY DEVELOPMENTS
10.11.4 SWOT ANALYSIS
10.12 MEDTRONIC
10.12.1 OVERVIEW
10.12.2 FINANCIALS
10.12.2.1 OVERALL FINANCIALS
10.12.3 KEY DEVELOPMENTS
10.13 NOVARTIS
10.13.1 OVERVIEW
10.13.2 FINANCIALS
10.13.2.1 OVERALL FINANCIALS
10.13.2.2 FINANCIALS BY REGION
10.13.2.3 FINANCIALS BY SEGMENT
10.14 PFIZER INC.
10.14.1 OVERVIEW
10.14.2 FINANCIALS
10.14.2.1 OVERALL FINANCIALS
10.14.2.2 NET REVENUE BY SEGMENT
10.14.2.3 NET REVENUE BY REGION
10.14.3 KEY DEVELOPMENTS
10.14.4 SWOT ANALYSIS
10.15 QIAGEN
10.15.1 OVERVIEW
10.15.1.1 BIOBASE GMBH (SUBSIDIARY)
10.15.1.1.1 OVERVIEW
10.15.2 FINANCIALS
10.15.2.1 OVERALL FINANCIALS
10.15.3 KEY DEVELOPMENTS (BIOBASE)
10.16 QUEST DIAGNOSTICS INC
10.16.1 OVERVIEW
10.16.2 FINANCIALS
10.16.2.1 OVERALL FINANCIALS
10.16.2.2 NET REVENUE BY SEGMENT
10.16.3 KEY DEVELOPMENTS
10.16.4 SWOT ANALYSIS
10.17 RANDOX LABORATORIES LTD.
10.17.1 OVERVIEW
10.17.2 FINANCIALS
10.17.3 KEY DEVELOPMENTS
10.17.4 SWOT ANALYSIS
10.18 ROCHE HOLDING AG-BR
10.18.1 OVERVIEW
10.18.2 FINANCIALS
10.18.2.1 OVERALL FINANCIALS
10.18.2.2 NET REVENUE BY SEGMENT
10.18.3 KEY DEVELOPMENTS
10.18.4 SWOT ANALYSIS
10.19 SANOFI PHARMA
10.19.1 OVERVIEW
10.19.2 FINANCIALS
10.19.2.1 OVERALL FINANCIALS
10.19.2.2 NET REVENUE BY SEGMENT
10.20 TAKEDA PHARMACEUTICAL COMPANY LIMITED
10.20.1 OVERVIEW
10.20.2 FINANCIALS
10.20.2.1 OVERALL FINANCIALS
10.20.3 KEY DEVELOPMENTS
10.20.4 SWOT ANALYSIS
10.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.
10.21.1 OVERVIEW
10.21.2 FINANCIALS
10.21.2.1 OVERALL FINANCIALS
10.21.2.2 NET REVENUE BY SEGMENT
10.21.2.3 NET REVENUE BY SEGMENT
10.21.3 KEY DEVELOPMENTS
10.21.4 SWOT ANALYSIS
10.22 AB-BIOTICS SA
10.22.1 OVERVIEW
10.23 CARIS LIFE SCIENCES
10.23.1 OVERVIEW
10.24 HEALTHCORE, INC.
10.24.1 OVERVIEW
10.25 IBM
10.25.1 OVERVIEW
10.26 INNVENTIS
10.26.1 OVERVIEW
10.27 INTEL CORPORATION
10.27.1 OVERVIEW
10.28 MOLECULAR HEALTH GMBH
10.28.1 OVERVIEW
10.29 PRECISION FOR MEDICINE
10.29.1 OVERVIEW
List of Tables
TABLE 1 LEADING COMPANIES IN THE PRECISION MEDICINE MARKET
TABLE 2 FACTORS IMPACTING THE BUYER’S BARGAINING POWER
TABLE 3 FACTORS IMPACTING THE SUPPLIER’S BARGAINING POWER
TABLE 4 FACTORS IMPACTING THE THREAT FROM SUBSTITUTE
TABLE 5 FACTORS IMPACTING THE THREAT FROM NEW ENTRANT
TABLE 6 REGULATORY BODIES IN PRECISION MEDICINE MARKET
TABLE 7 CONSORTIUMS IN PRECISION MEDICINE MARKET
TABLE 8 ALLIANCES/ASSOCIATIONSIN PRECISION MEDICINE MARKET
TABLE 9 GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)
TABLE 10 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)
TABLE 11 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION)
TABLE 12 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION)
TABLE 13 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014- 2022 ($BILLION)
TABLE 14 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION)
TABLE 15 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION)
TABLE 16 KEY DEVELOPMENTS IN DIAGNOSTIC COMPANIES(2015)
TABLE 17 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)
TABLE 18 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION)
TABLE 19 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014- 2022 ($BILLION)
TABLE 20 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)
TABLE 21 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION)
TABLE 22 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014- 2022 ($BILLION)
TABLE 23 GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)
TABLE 24 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
TABLE 25 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)
TABLE 26 BENEFITS OF COMPANION DIAGNOSTICS
TABLE 27 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
TABLE 28 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014- 2022 ($MILLION)
TABLE 29 EXAMPLES OF BIOBANKING INITIATIVES ACROSS SELECTED OECD COUNTRIES
TABLE 30 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
TABLE 31 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)
TABLE 32 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
TABLE 33 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)
TABLE 34 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
TABLE 35 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)
TABLE 36 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
TABLE 37 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)
TABLE 38 GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($BILLION)
TABLE 39 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)
TABLE 40 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)
TABLE 41 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION)
TABLE 42 PRECISION MEDICINE DRUGS AND RELEVANT GENES: ONCOLOGY
TABLE 43 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO ONCOLOGY
TABLE 44 KEY DEVELOPMENTS (2013-2015)
TABLE 45 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)
TABLE 46 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)
TABLE 47 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 48 PRECISION MEDICINE DRUGS AND RELEVANT GENES: CARDIOVASCULAR
TABLE 49 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO CARDIOVASCULAR
TABLE 50 KEY DEVELOPMENTS (2014-2015)
TABLE 51 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
TABLE 52 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($MILLION)
TABLE 53 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 54 PRECISION MEDICINE DRUGS AND RELEVANT GENES: NEUROLOGY
TABLE 55 PRECISION MEDICINE DRUGS AND RELEVANTGENES: PSYCHIATRIC DISORDERS
TABLE 56 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO PSYCHIATRIC DISORDERS
TABLE 57 PSYCHIATRIC DISORDERS: KEY DEVELOPMENTS (2014-2015)
TABLE 58 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
TABLE 59 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($MILLION)
TABLE 60 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 61 PRECISION MEDICINE DRUGS AND RELEVANT GENES: INFECTIOUS DISEASES
TABLE 62 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
TABLE 63 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($MILLION)
TABLE 64 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014- 2022 ($MILLION)
TABLE 65 PRECISION MEDICINE DRUGS AND RELEVANT GENES: OTHER DISEASES
TABLE 66 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO OTHER DISEASES
TABLE 67 GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION)
TABLE 68 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)
TABLE 69 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)
TABLE 70 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014- 2022 ($BILLION)
TABLE 71 EUROPE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)
TABLE 72 EUROPE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014- 2022 ($BILLION)
TABLE 73 APAC: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)
TABLE 74 APAC: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($MILLION)
TABLE 75 ROW: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
TABLE 76 ROW: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($MILLION)
List of Figures
FIGURE 1 PRECISION MEDICINE MARKET STUDY
FIGURE 2 BIS RESEARCH METHODOLOGY
FIGURE 3 DIFFERENT PHASES OF RESEARCH METHODOLOGY FOR THE GLOBAL MARKET
FIGURE 4 PRECISION MEDICINE MARKET: RESEARCH METHODOLOGY
FIGURE 5 GLOBAL PRECISION MEDICINE MARKET SHARE, BY ECOSYSTEM, 2014-2022 ($BILLION)
FIGURE 6 GLOBAL PRECISION MEDICINE MARKET SIZE, BY SUB-MARKET TYPE, 2014 – 2022 (BILLION)
FIGURE 7 GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERPEUTIC APPLICATION, 2014 – 2022 (BILLION)
FIGURE 8 GLOBAL PRECISION MEDICINE MARKET SIZE, BY GEOGRAPHY, 2014 – 2022 ($BILLION)
FIGURE 9 TIMELINE OF PRECISION MEDICINE
FIGURE 10 PRECISION MEDICINE: BENEFITS
FIGURE 11 EXAMPLES: APPLIED AREAS OF PRECISION MEDICINE
FIGURE 12 ELEMENTS OF PRECISION MEDICINE TECHNOLOGY
FIGURE 13 DIFFERENT TYPE OF DATA USED BY BIG DATA COMPANIES
FIGURE 14 PRECISION MEDICINE : AREAS OF INTEREST
FIGURE 15 PRECISION MEDICINE: PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2015)
FIGURE 16 PRECISION MEDICINE : MERGERS & ACQUISITIONS( 2015)
FIGURE 17 PRECISION MEDICINE : KEY PRODUCT LAUNCH & DEVELOPMENTS (2015)
FIGURE 18 PRECISION MEDICINE: KEY BUSINESS EXPANSIONS & CONTRACTS (2015)
FIGURE 19 PRECISION MEDICINE : KEY PATENTS/ APPROVALS ( 2015)
FIGURE 20 PRECISION MEDICINE: EVENTS & RECOGNITION (2015)
FIGURE 21 MARKET DRIVERS AND CHALLENGES
FIGURE 22 BENEFITS OF PRECISION MEDICINE TO PATIENTS
FIGURE 23 PRECISION MEDICINE MARKET CHALLENGES: IMPACT ANALYSIS
FIGURE 24 MAJOR BARRIERS CAUSED BY REGULATION AND STANDARDS
FIGURE 25 DOWNSIZING COST OF GENOME SEQUENCING
FIGURE 26 FLOW CHART OF PRECISION MEDICINE
FIGURE 27 VALUE CHAIN ANALYSIS
FIGURE 28 PRECISION MEDICINE MARKET: PORTER FIVE FORCE ANALYSIS
FIGURE 29 FACTORS IMPACTING THE DEGREE OF COMPETITION
FIGURE 30 ROLES AND RESPONSIBILITIES OF HEALTHCARE POLICY MAKERS
FIGURE 31 ROLE OF FDA IN PRECISION MEDICINE
FIGURE 32 CLASSIFICATION OF MEDICAL DEVICES
FIGURE 33 GLOBAL PRECISION MEDICINE MARKET BY ECOSYSTEM PLAYERS
FIGURE 34 ROLE OF PHARMACEUTICALS AND BIOTECH COMPANIES
FIGURE 35 CHALLENGES FACED BY PHARMA & BIOTECH COMPANIES
FIGURE 36 KEY DEVELOPMENTS IN PHARMA & BIOTECH COMPANIES(2015)
FIGURE 37 DIAGNOSTIC TESTS BENEFITS FOR STAKEHOLDERS
FIGURE 38 CHALLENGES FACED BY DIAGNOSTIC COMPANIES
FIGURE 39 BENEFITS OF BIG DATA
FIGURE 40 TRANSFORMATION OF MEDICINE
FIGURE 41 BASIC INGREDIENTS PROVIDED BY BIG DATA FOR PRECISION MEDICINE
FIGURE 42 CHALLENGES FACED BY BIG DATA COMPANIES
FIGURE 43 KEY DEVELOPMENTS IN HEALTHCARE IT/BIG DATA COMPANIES(2015)
FIGURE 44 OECD RECOMMENDATIONS ON THE GOVERNANCE OF CLINICAL TRIALS
FIGURE 45 TYPES OF PRECISION MEDICINE SUB-MARKET
FIGURE 46 LIST OF APPROVED COMPANION DIAGNOSTIC DEVICES
FIGURE 47 FUNCTION OF BIOMARKERS
FIGURE 48 LIST OF BIOBANKS
FIGURE 49 BIOBANKS SERVICES
FIGURE 50 DEVELOPMENT IN PGX
FIGURE 51 MODEL SYSTEMS USED IN PGX
FIGURE 52 CHALLENGES OF PGX STUDIES
FIGURE 53 FIGURE TITLE MISSING
FIGURE 54 MOLECULAR DIAGNOSTICS: APPLICATION
FIGURE 55 MOLECULAR DIAGNOSTICS: BENEFITS
FIGURE 56 GLOBAL PRECISION MEDICINE MARKET: BY THERAPEUTICS
FIGURE 57 TARGET SCOPE OF PRECISION MEDICINE BY CANCER TYPES
FIGURE 58 GLOBAL PRECISION MEDICINE MARKET CLASSIFICATION, BY GEOGRAPHY
FIGURE 59 KEY DRIVERS FOR PRECISION MEDICINE: NORTH AMERICA
FIGURE 60 OBJECTIVES OF THE PRECISION MEDICINE INITIATIVE
FIGURE 61 APAC: MARKET CHALLENGES
FIGURE 62 ABBOTT: OVERALL FINANCIALS ($BILLION), 2012-2014
FIGURE 63 ABBOTT: NET REVENUE BY SEGMENTS ($BILLION), 2012-2014
FIGURE 64 ABBOTT: NET REVENUE BY REGION, 2012-2014 ($BILLION)
FIGURE 65 ABBOTT: SWOT ANALYSIS
FIGURE 66 ALMAC: SWOT ANALYSIS
FIGURE 67 ASURAGEN: SWOT ANALYSIS
FIGURE 68 BIOMERIEUX: OVERALL FINANCIALS ($MILLION), 2012-2014
FIGURE 69 BIOMERIEUX: NET REVENUE BY REGION, 2014
FIGURE 70 BIOMERIEUX: NET REVENUE BY SEGMENT, 2014
FIGURE 71 BIOMERIEUX: SWOT ANALYSIS
FIGURE 72 CEPHEID: OVERALL FINANCIALS, 2012-2014 ($MILLION)
FIGURE 73 CEPHEID: NET REVENUE, BY SEGMENTS, 2012-2014 ($MILLION)
FIGURE 74 CEPHEID: NET REVENUE, BY REGION, 2012-2014 ($MILLION)
FIGURE 75 CEPHEID: SWOT ANALYSIS
FIGURE 76 GE CORPORATION: OVERALL FINANCIALS, 2012-2014 ($BILLION)
FIGURE 77 GE CORPORATION: NET REVENUE, BY SEGMENTS, 2012-2014 ($MILLION)
FIGURE 78 GSK: OVERALL FINANCIALS, 2012-2014 ($BILLION)
FIGURE 79 GSK: NET REVENUE BY SEGMENT, 2014 ($BILLION)
FIGURE 80 GSK: NET REVENUE BY REGION, 2014 ($BILLION)
FIGURE 81 GSK: NET REVENUE BY THERAPEUTICS, 2014 ($BILLION)
FIGURE 82 J&J: OVERALL FINANCIALS, 2012 - 2014 ($BILLION)
FIGURE 83 J&J: NET REVENUE BY SEGMENT, 2012 - 2014 ($MILLION)
FIGURE 84 J&J: NET REVENUE BY REGION, 2012 - 2014 ($MILLION)
FIGURE 85 LABCORP: OVERALL FINANCIALS ($MILLION), 2012-2014
FIGURE 86 NET REVENUE BY SEGMENTS, 2012-2014($MILLION)
FIGURE 87 LABCORP: SWOT ANALYSIS
FIGURE 88 MEDTRONIC: OVERALL FINANCIALS, 2012 - 2014 ($MILLION)
FIGURE 89 NOVARTIS: OVERALL FINANCIALS, 2012 - 2014 ($BILLION)
FIGURE 90 NOVARTIS: NET REVENUE BY REGION, 2014 ($BILLION)
FIGURE 91 NOVARTIS: NET REVENUE BY SEGMENT, 2014 ($BILLION)
FIGURE 92 PFIZER: OVERALL FINANCIALS, 2012 – 2014 ($BILLION)
FIGURE 93 PFIZER: NET REVENUE, BY SEGMENT, 2012-2014 ($MILLION)
FIGURE 94 PFIZER: NET REVENUE, BY REGION, 2012-2014 ($BILLION)
FIGURE 95 PFIZER : SWOT ANALYSIS
FIGURE 96 QIAGEN: OVERALL FINANCIALS ($MILLION), 2012-2014
FIGURE 97 QIAGEN: NET REVENUE BY REGION ($MILLION), 2014
FIGURE 98 QIAGEN: NET REVENUE BY SEGMENT, 2014
FIGURE 99 QUEST: OVERALL FINANCIALS, 2012 - 2014 ($MILLION)
FIGURE 100 QUEST: NET REVENUE, BY SEGMENT, 2012 - 2014 ($MILLION)
FIGURE 101 QUEST: SWOT ANALYSIS
FIGURE 102 ROCHE: OVERALL FINANCIALS, 2012-2014 ($BILLION)
FIGURE 103 ROCHE: NET REVENUE, BY SEGMENTS, 2012-2014 ($BILLION)
FIGURE 104 ROCHE: SWOT ANALYSIS
FIGURE 105 SANOFI PHARMA: OVERALL FINANCIALS, 2012-2014($BILLION)
FIGURE 106 SANOFI PHARMA: NET REVENUE, BY SEGMENTS, 2012-2014 ($BILION)
FIGURE 107 TAKEDA: OVERALL FINANCIALS, 2012-2014 ($BILLION)
FIGURE 108 TAKEDA: SWOT ANALYSIS
FIGURE 109 TEVA: OVERALL FINANCIALS, 2012 – 2014 ($BILLION)
FIGURE 110 TEVA: NET REVENUE SHARE, BY SEGMENT (2014)
FIGURE 111 TEVA: NET REVENUE SHARE, BY REGION (2014)
FIGURE 112 TEVA: SWOT ANALYSIS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report